TEM Tempus AI, Inc.
Company Analysis
Latest News
🟢 Tempus AI is trading 4% up today as software and growth stocks rally
Tempus AI is trading 4% up at $71.24 as software and growth stocks rally following strong Nvidia, Salesforce, and CrowdStrike results. - The move appears...
🟢 Tempus AI is trading 4.8% up today
Tempus AI is trading 4.8% up at $69.34 after opening-market volatility, with no reliable company-specific explanation for the gain. - The move follows an...
Casdin Capital Exits Tempus AI (TEM) Position in Q2
In a notable portfolio shift, life sciences investment firm Casdin Capital fully exited its position in Tempus AI (TEM) during the second quarter of 2026. The...
Tempus AI Secures FDA Clearance for ECG Software, Targeting Pulmonary Hypertension
Tempus AI, Inc. received FDA 510(k) clearance for its AI-enabled software, Tempus ECG-PH. The device analyzes standard 12-lead electrocardiograms to detect...
🟢 Tempus AI is trading 5.5% up today after Moderna’s Phase 3 results strengthened deal confidence
Tempus AI is trading 5.5% up now at $70.33 after investors continued rewarding its $1.5 billion Personalis acquisition, whose genomic technology supports...
🟢 Tempus AI is trading 10.29% up today as Moderna vaccine results strengthen Personalis deal confidence
Tempus AI is trading $67.55 (+10.29%) as investors connect positive Phase 3 results for Moderna’s personalized cancer vaccine with Personalis, which Tempus AI...
🟢 Tempus AI is trading 6.29% up today as Merck–Moderna trial success validates Personalis-linked sequencing
Tempus AI is trading 6.29% up now at $65.11 as investors continue rewarding Wednesday’s landmark Merck–Moderna cancer-vaccine trial results. - Phase 3 success...
Tempus AI Rockets 22% on a Cancer Vaccine Breakthrough — But Can a Single Trial Justify a $1.5 Billion Bet?
Shares of Tempus AI surged 22% to $60.23 Wednesday after a landmark clinical trial handed the company an unexpected windfall of validation. A personalized...
Tempus AI Surges, as Cancer Vaccine Success Validates $1.5B Personalis Deal
Tempus AI shares surged more than 20% on Wednesday. The rally followed news that a personalized mRNA cancer vaccine from Merck and Moderna succeeded in a...
🟢 Tempus AI is trading 12.64% up today; no clear catalyst identified
Tempus AI is trading 12.64% up at $55.40, with no clear company-specific catalyst identified for August 19, 2026. - Latest listed releases were the August 4...
🟢 Tempus AI is trading 13.19% up in pre-market despite no identified catalyst
Tempus AI is trading 13.19% up at $55.87 after no clear company-specific announcement was identified for August 19, 2026. - The latest listed company releases...
🟢 Tempus AI is trading 5% up in pre-market; catalyst unclear
Tempus AI is trading at $52.03 (+5.41%) with no clear fresh catalyst identified. - No fresh August 19, 2026 company-specific announcement or earnings release...
🔴 Tempus AI is trading 4.07% down today amid broader technology and AI-stock weakness
Tempus AI is trading 4.07% down now at $49.54, moving with broader weakness in technology and AI stocks. • The Nasdaq Composite is down 1.22%, and the S&P 500...
🔴 Tempus AI is trading 4.16% down today; specific catalyst remains unclear
Tempus AI is trading at $52.03 (-4.16%), with the specific catalyst unclear. - No clear company-specific announcement or analyst action surfaced for August...
🟢 Tempus AI is trading 4.72% up today as August 7’s software rally extends
Tempus AI is trading $54.51 (+4.72%) as the advance appears to extend August 7’s 12.86% rally, when strong Atlassian and Doximity results lifted software...
🟢 Tempus AI is trading 11.22% up today after Atlassian and Doximity results lifted software stocks
Tempus AI is trading at $51.29, up 11.22%, as software stocks rise after strong Atlassian and Doximity results lifted the sector. - A weaker-than-expected...
🟢 Tempus AI is trading 9.2% up today following a broader software-sector rally
Tempus AI is trading 9.2% up at $50.26, following a broader software-sector rally. - The IGV software ETF is up 3.48% during regular trading as Atlassian and...
Tempus AI Validates PRISM2 Model, Outperforming Rivals in Nature Medicine Study
Tempus AI announced a new study in Nature Medicine validating its PRISM2 AI-powered pathology model. The model, developed in collaboration with Microsoft,...
Tempus AI's second quarter revenue rose 22% as it swung to a surprise profit and raised its 2026 outlook.
Tempus AI reported second quarter revenue of $382.5 million, a 22% increase year-over-year, and a significant beat on profitability with a GAAP EPS of $0.03...
🟢 Tempus AI is trading 4.1% up today ahead of Q2 earnings and a Personalis acquisition update
Tempus AI is trading at $43.24 (+4.1%) as investors position ahead of its Q2 2026 earnings report and an integration update on the $1.5 billion all-stock...